Infratil Limited
Investment Thesis
Infratil owns a portfolio of infrastructure assets anchored by CDC Data Centres, a business with contracted revenue, a weighted average lease term of 28.7 years including options, and investment-grade counterparties providing more than 90% of its revenue. The question for an investor is not whether the underlying assets are good; they plainly are. It is whether the current share price already captures that quality, leaving little room for error if any single assumption, the pace of CDC's deployment, the persistence of the holding company discount, or the path of interest rates, does not go to plan.
The Business
Infratil is an externally managed infrastructure investment company, dual-listed on the NZX and ASX and run by Morrison & Co under a fee-based management agreement. Its portfolio spans CDC Data Centres (the largest holding at roughly half of portfolio value), One NZ (New Zealand mobile and fixed-line telecommunications), Longroad Energy (US renewables development), Wellington Airport, a cluster of healthcare assets, Kao Data in the UK, a stake in Contact Energy, and several early-stage development investments. Reporting is in New Zealand dollars, while the ASX-quoted share price is in Australian dollars.
Recent Performance
In the half-year to 30 September 2026 (HY27), Infratil's proportionate operational EBITDAF (its preferred measure, since CDC and Longroad are equity-accounted rather than consolidated) rose 28% to NZ$711 million (HY26: NZ$555 million). CDC's EBITDAF rose 84% to A$339 million and One NZ's 10% to NZ$325 million (including about NZ$20 million of non-recurring and timing benefits, among them an intellectual property sale). Infratil lifted its FY27 proportionate operational EBITDAF guidance to NZ$1,370 million to NZ$1,440 million, up from Investor Day (NZ$1,320m-1,420m) and May (NZ$1,300m-1,400m), and CDC's FY27 EBITDAF guidance to A$730m to A$770m (from A$710m to A$750m). Infratil reported a net parent loss of NZ$248 million (HY26: surplus of NZ$606 million); the half included a NZ$256 million incentive fee provision, driven by CDC's higher valuation and subject to year-end valuations. Net portfolio asset value (post fees) rose 10% to NZ$17.94 a share (31 March 2026: NZ$16.26), and the partially imputed interim dividend is 7.4 NZ cents per share (HY26: 7.25 cents), with 1.2 cents of imputation credits attached, a record date of 2 December and payment on 21 December 2026; the dividend reinvestment plan operates with a 2% discount. The share price has not followed: after an all-time high during the half, it fell after 30 September to levels last seen in early May, before CDC's 555MW contract. The company cites higher interest rates, renewed uncertainty about the pace of and returns on AI investment, and power supply problems at a listed Australian data centre provider's site, and notes some moderation of earlier forecasts for new computing and data centre capacity, which it says does not change its investment thesis.
Outlook
The company expects earnings to keep accelerating as contracted capacity comes online: CDC's 1.1 gigawatts of contracted capacity is expected to deliver A$2.2 billion of annualised EBITDAF once fully deployed by the end of FY29, and Longroad expects its operating and in-construction capacity to exceed 14GW by the end of 2029, lifting its operating fleet run-rate EBITDAF to around US$1.2 billion. CDC's figure is contracted capacity being switched on rather than a demand forecast (Longroad has contracted 3.1GW of its 2027-2029 development plan), which gives the growth path more certainty than a typical earnings projection. The catch is cash: in HY27 the parent's NZ$100.3 million operating cash inflow did not cover NZ$126.1 million of incentive fees and NZ$95.4 million of dividends, and the company says CDC is on track to become a cash flow contributor in the medium term. The interim dividend rose 2% to 7.4 cents per share, well short of the pace of earnings growth, because cash is being retained to fund the build-out rather than distributed.
Key Risks
The single biggest swing factor in this investment case is whether the current discount to net asset value proves structural or temporary. If it persists indefinitely despite strong operating performance underneath, that is a meaningfully different outcome for shareholders than a discount that narrows as CDC's cash distributions grow. A further rise in bond yields presents a separate risk: higher rates lower the independent valuations of long-dated infrastructure, as higher US base rates did to Longroad's valuation in HY27, while a higher forward yield curve held CDC's broadly flat in the September quarter despite contracting progress, even though the contracted revenue underneath is unaffected. Finally, Morrison's fees took NZ$200.6 million of the NZ$263.8 million Infratil received from its portfolio companies in HY27, meaning shareholders capture a smaller share of CDC's growth than the headline earnings numbers suggest, a structural drag that is unlikely to change materially in the next few years.
What to Watch
- Nov 2027 HY28 results, watching for confirmation that CDC is tracking toward its EBITDAF targets — this is the thesis-defining event, since the company expects CDC to become a cash flow contributor in the medium term, the trigger for the cash flow inflection the business case depends on.
- May 2027 FY27 results versus CDC's EBITDAF guidance — a beat would support the contracted delivery assumption underpinning the growth outlook.
Latest Developments
With the HY27 result on 18 November 2026, Infratil raised its FY27 proportionate operational EBITDAF guidance for the second time since May, and CDC's FY27 EBITDAF guidance has been lifted three times in 2026: to a formal A$680m to A$720m in March (from an earlier indication of about A$660 million), to A$710m to A$750m in September and to A$730m to A$770m in November. Updated independent valuations at 30 September cut Longroad's value by US$455 million (11.3%) to US$3.56 billion, mainly on a higher assessed cost of capital, a more conservative view of its long-term pipeline and lower forecast merchant power prices; Infratil's 43.5% interest is valued at NZ$2,350.4 million. CDC's 555MW contract, which CDC describes as the largest data centre contract in Australia's history, was announced on 5 May 2026, before the FY26 result. Infratil intends to lodge a PDS on 20 November 2026 for a capital bond offer to replace its maturing IFT280s in December, the Qscan sale process is continuing, and the company sees potential for another NZ$1 billion or more of divestments over the medium term.
Business Quality
Company Description
Infratil does not operate businesses directly; it owns stakes in them and pays Morrison & Co a fee to manage the portfolio. CDC Data Centres is the largest holding at roughly half of portfolio value, providing hyperscale and government-grade data centre capacity across Australia and New Zealand. One NZ is a New Zealand mobile and fixed-line telecommunications provider. Longroad Energy develops and operates US wind, solar and battery assets. Smaller holdings include Wellington Airport, a cluster of healthcare businesses (diagnostic imaging and teleradiology), Kao Data in the UK, a stake in listed New Zealand generator Contact Energy, and several early-stage development investments.
Where the Growth Is
CDC Data Centres is the engine of the whole portfolio. Its FY27 EBITDAF guidance is A$730 million to A$770 million, and the company expects its 1.1 gigawatts of contracted capacity to deliver A$2.2 billion of annualised EBITDAF once fully deployed by the end of FY29, against A$339 million in HY27. CDC paid Infratil NZ$22.3 million in HY27, and the company says CDC is on track to become a cash flow contributor in the medium term; larger distributions from CDC are what would let the parent cover its fees and dividends from operating cash flow.
Competitive Position
CDC's advantage rests on physical scarcity rather than brand or switching costs. Grid connections for large data centre campuses carry multi-year lead times, as Infratil noted at its September Investor Day, which limits how quickly competitors can add supply regardless of capital available. CDC's contracts have a weighted average lease term of 28.7 years including options, with investment-grade counterparties providing more than 90% of revenue, which locks in cash flow well beyond any single technology cycle. That advantage looks set to widen rather than narrow as grid constraints intensify across the National Electricity Market, favouring incumbents who already hold secured connections over new entrants still queuing for them.
Management & Capital Discipline
Under Morrison & Co's management, Infratil calculates its internal rate of return at 37.1% on CDC and 39.3% on Longroad (in NZ$, to 30 September 2026), and CDC's FY27 EBITDAF guidance has been raised three times in 2026, a strong record of identifying and developing scarce infrastructure assets. Capital recycling has been active, including the 5% Contact Energy sell-down in May (about NZ$495 million), the Fortysouth sale (NZ$217 million) and the continuing Qscan sale process, freeing capital to fund continued CDC deployment without relying solely on debt or new equity. The honest tension is this: the company noted with the HY27 result that staff and directors had been active buyers of shares in a personal capacity in the preceding months, a sign of alignment with shareholders, but the management fees themselves took about three-quarters of the cash Infratil received from its portfolio companies in HY27, a structural drag on shareholder cash returns that persists alongside the strong investment returns.
Financial Position
The parent company carries low leverage relative to portfolio value (a 14.2% loan-to-value ratio at 30 September) and holds substantial liquidity (about NZ$1.4 billion available, with a BBB+ credit rating), giving it room to keep funding growth across the portfolio. Financial health across the group is strong, supported by the long-dated, contracted nature of CDC's revenue and the stability of One NZ's cash flow. The main financial constraint is timing, not solvency: the parent's operating cash flow does not yet cover incentive fees and dividends while CDC is under construction, and the gap is funded by divestments and debt, a position that is manageable given the balance sheet but worth monitoring.
Read the full report
Our complete analysis of Infratil Limited includes: